access
Questions about access related to GLP-1 medications.
4 questions in this category
Is Semaglutide Still in Shortage in 2026?
Novo Nordisk declared the shortage resolved in early 2025, which triggered FDA restrictions on compounding. However, compounded semaglutide remains available through many telehealth platforms while legal challenges continue. Check with your provider for current status.
semaglutideWhen Will Retatrutide Be FDA Approved?
Eli Lilly launched the Phase 3 TRIUMPH program in 2024. FDA submission is expected in 2026, with potential approval in 2026-2027. Phase 3 results from the TRIUMPH-3 trial are expected in late 2025.
retatrutideCan I Get Retatrutide Now?
Not through standard channels — it's not FDA approved yet. Some clinical trial sites are enrolling patients in the TRIUMPH Phase 3 program. Otherwise, tirzepatide (Mounjaro/Zepbound) is the closest currently available alternative, also made by Eli Lilly with similar mechanisms.
retatrutideWill Compounded Retatrutide Be Available?
Too early to know. Compounding depends on whether a shortage is declared after approval. Given FDA's recent moves to restrict compounded semaglutide and tirzepatide, it's possible FDA will tightly control retatrutide from day one. Availability at launch is uncertain.
retatrutideBrowse Other Categories
Still Have Questions?
Browse all 429+ frequently asked questions or compare GLP-1 providers to find the right fit.